Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Other Non-Current Liabilities (2020 - 2022)

Historic Other Non-Current Liabilities for Caribou Biosciences (CRBU) over the last 3 years, with Q1 2022 value amounting to $9000.0.

  • Caribou Biosciences' Other Non-Current Liabilities changed N/A to $9000.0 in Q1 2022 from the same period last year, while for Mar 2022 it was $9000.0, marking a year-over-year change of. This contributed to the annual value of $17000.0 for FY2021, which is 9034.09% down from last year.
  • Per Caribou Biosciences' latest filing, its Other Non-Current Liabilities stood at $9000.0 for Q1 2022.
  • In the past 5 years, Caribou Biosciences' Other Non-Current Liabilities registered a high of $176000.0 during Q4 2020, and its lowest value of $9000.0 during Q1 2022.
  • For the 3-year period, Caribou Biosciences' Other Non-Current Liabilities averaged around $103600.0, with its median value being $153000.0 (2021).
  • Data for Caribou Biosciences' Other Non-Current Liabilities shows a peak YoY increase of 9034.09% (in 2021) and a maximum YoY decrease of 9034.09% (in 2021) over the last 5 years.
  • Caribou Biosciences' Other Non-Current Liabilities (Quarter) stood at $176000.0 in 2020, then tumbled by 90.34% to $17000.0 in 2021, then tumbled by 47.06% to $9000.0 in 2022.
  • Its last three reported values are $9000.0 in Q1 2022, $17000.0 for Q4 2021, and $153000.0 during Q3 2021.